Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALZN NASDAQ:ENTO NASDAQ:PTIX NASDAQ:SXTP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.06+0.5%$1.40$0.84▼$8.22$4.01M0.11118,204 shs3,566 shsENTOEntero Therapeutics$3.42+20.0%$2.34$0.32▼$5.84$5.43M1.192.80 million shs259,890 shsPTIXAtrinsic$0.55-15.4%$0.61$0.25▼$14.28$996K1.1341,381 shs300 shsSXTP60 Degrees Pharmaceuticals$1.48+1.0%$1.92$1.29▼$14.68$3.92M2.693.14 million shs17,945 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-1.87%-6.25%+22.45%-45.31%-82.27%ENTOEntero Therapeutics0.00%+35.71%+63.64%+27.61%+177.17%PTIXAtrinsic-17.72%-18.75%0.00%+71.05%-79.10%SXTP60 Degrees Pharmaceuticals-4.55%-11.45%-16.48%-63.70%-84.09%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALZNAlzamend Neuro$1.06+0.5%$1.40$0.84▼$8.22$4.01M0.11118,204 shs3,566 shsENTOEntero Therapeutics$3.42+20.0%$2.34$0.32▼$5.84$5.43M1.192.80 million shs259,890 shsPTIXAtrinsic$0.55-15.4%$0.61$0.25▼$14.28$996K1.1341,381 shs300 shsSXTP60 Degrees Pharmaceuticals$1.48+1.0%$1.92$1.29▼$14.68$3.92M2.693.14 million shs17,945 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALZNAlzamend Neuro-1.87%-6.25%+22.45%-45.31%-82.27%ENTOEntero Therapeutics0.00%+35.71%+63.64%+27.61%+177.17%PTIXAtrinsic-17.72%-18.75%0.00%+71.05%-79.10%SXTP60 Degrees Pharmaceuticals-4.55%-11.45%-16.48%-63.70%-84.09%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALZNAlzamend Neuro 2.00Hold$28.002,554.03% UpsideENTOEntero Therapeutics 1.00SellN/AN/APTIXAtrinsic 1.00SellN/AN/ASXTP60 Degrees Pharmaceuticals 2.25Hold$14.10850.13% UpsideCurrent Analyst Ratings BreakdownLatest PTIX, SXTP, ENTO, and ALZN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026ALZNAlzamend Neuro Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)4/9/2026SXTP60 Degrees Pharmaceuticals Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$11.20 ➝ $4.203/27/2026SXTP60 Degrees Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALZNAlzamend NeuroN/AN/AN/AN/A$4.95 per shareN/AENTOEntero TherapeuticsN/AN/AN/AN/A($2.45) per shareN/APTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ASXTP60 Degrees Pharmaceuticals$1.41M2.78N/AN/A($5.85) per share-0.25Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALZNAlzamend Neuro-$4.51M-$2.16N/AN/AN/AN/A-177.52%-140.41%7/28/2026 (Estimated)ENTOEntero Therapeutics-$18.06M-$1.69N/AN/AN/AN/A-461.02%-14.72%5/13/2026 (Estimated)PTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%N/ASXTP60 Degrees Pharmaceuticals-$7.36M-$13.88N/AN/AN/A-550.67%N/A-132.47%5/21/2026 (Estimated)Latest PTIX, SXTP, ENTO, and ALZN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026SXTP60 Degrees Pharmaceuticals-$0.76N/AN/AN/A$0.44 millionN/A3/11/2026Q3 2026ALZNAlzamend Neuro-$0.53-$0.5780-$0.0480-$0.58N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALZNAlzamend NeuroN/AN/AN/AN/AN/AENTOEntero TherapeuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ASXTP60 Degrees PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALZNAlzamend NeuroN/A1.991.99ENTOEntero TherapeuticsN/A2.622.62PTIXAtrinsicN/A0.290.29SXTP60 Degrees PharmaceuticalsN/A2.662.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALZNAlzamend Neuro49.61%ENTOEntero Therapeutics12.30%PTIXAtrinsic7.97%SXTP60 Degrees Pharmaceuticals7.96%Insider OwnershipCompanyInsider OwnershipALZNAlzamend Neuro1.39%ENTOEntero Therapeutics0.75%PTIXAtrinsic8.00%SXTP60 Degrees Pharmaceuticals1.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALZNAlzamend Neuro43.81 million3.75 millionNo DataENTOEntero Therapeutics91.59 million3.34 millionN/APTIXAtrinsic21.81 million1.78 millionNot OptionableSXTP60 Degrees Pharmaceuticals32.64 million2.59 millionNot OptionablePTIX, SXTP, ENTO, and ALZN HeadlinesRecent News About These CompaniesShort Interest in 60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) Rises By 13.4%May 3, 2026 | americanbankingnews.com60 Degrees Pharmaceuticals (SXTP) price target decreased by 19.89% to 14.38April 30, 2026 | msn.com60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel WebsiteApril 15, 2026 | markets.businessinsider.com60 Degrees Pharmaceuticals Inc. (SXTP) Upgraded to Buy: Here's What You Should KnowApril 3, 2026 | zacks.comInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comFInfrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 2, 2026 | freep.comF60 Degrees Pharmaceuticals Announces 2025 Annual ResultsMarch 31, 2026 | globenewswire.com60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut ExtractMarch 18, 2026 | globenewswire.com60 Degrees Pharmaceuticals Updates Opinion for ATM ProgramMarch 14, 2026 | theglobeandmail.comWhat's going on with 60 Degrees Pharmaceuticals on Friday?March 13, 2026 | msn.com60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical TrialMarch 11, 2026 | globenewswire.com60 Degrees Pharmaceuticals (SXTP) Partners With GoodRx to Expand Access to ARAKODAFebruary 24, 2026 | insidermonkey.com60 Degrees Pharmaceuticals (SXTP) price target increased by 300.00% to 17.95February 4, 2026 | msn.com60 Degrees Pharmaceuticals shares slide after unveiling GoodRx collaborationFebruary 2, 2026 | msn.com60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx PartnershipFebruary 2, 2026 | globenewswire.com60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx UseJanuary 29, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals shares slide after Nasdaq flags delisting riskJanuary 26, 2026 | msn.com60 Degrees Pharmaceuticals stock tumbles after Nasdaq delisting noticeJanuary 26, 2026 | au.investing.com60 Degrees Pharmaceuticals stock soars on new telehealth partnershipJanuary 22, 2026 | za.investing.com60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria PreventionJanuary 22, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026Fastenal Stock Slips After Earnings: 5 Reasons To Buy the Dip By Thomas Hughes | April 14, 2026Harley Pivots Hard: Can New Bikes Fix an Old Brand?By Jeffrey Neal Johnson | May 9, 2026PTIX, SXTP, ENTO, and ALZN Company DescriptionsAlzamend Neuro NASDAQ:ALZN$1.06 +0.01 (+0.48%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.Entero Therapeutics NASDAQ:ENTO$3.42 +0.57 (+20.00%) As of 05/8/2026Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Atrinsic NASDAQ:PTIX$0.55 -0.10 (-15.38%) As of 09:51 AM EasternProtagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.60 Degrees Pharmaceuticals NASDAQ:SXTP$1.48 +0.01 (+0.95%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
